Enhancement of in vitro and in vivo microdialysis recovery of SB-265123 using Intralipid® and Encapsin® as perfusates

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 1, 2003, Pages 17-25

  Ward, Keith W ^a   Medina, Sara J ^a   Portelli, Samm T ^a   Mahar Doan, Kelly M ^a   Spengler, Michael D ^b   Ben, Michael M ^a   Lundberg, David ^a   Levy, Mark A ^a   Chen, Emile P ^a  

^a GLAXOSMITHKLINE   (United States)

^b Preclin Drug Disc Microbial Musc   (United States)

Author keywords

Encapsin ; Intralipid ; Microdialysis; Pharmacokinetics; Probe recovery

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; 10,11 DIHYDRO 3 [3 (PYRIDIN 2 YLAMINO) 1 PROPYLOXY] 5H DIBENZO[A,D]CYCLOHEPTANE 10 ACETIC ACID; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; INTRALIPID; RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; MICRODIALYSIS; NONHUMAN; PERFUSION; PLASMA PROTEIN BINDING; RAT;

ACETIC ACIDS; AMINOPYRIDINES; ANIMALS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; CYCLODEXTRINS; FAT EMULSIONS, INTRAVENOUS; MALE; MICRODIALYSIS; RATS;

EID: 0037239625     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.332     Document Type: Article

References (19)

1. Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res 1997; 14: 267-288.
2. Davies M. A review of microdialysis sampling for pharmacokinetic applications. Anal Chim Acta 1999; 379: 227-249.
3. Stenken JA. Methods and issues in microdialysis calibration. Anal Chim Acta 1999; 379: 337-358.
4. Ungerstedt U. Introduction to microdialysis. In Microdialysis in the Neurosciences, Robinson TE, Justice Jr JB (eds). Elsevier: Amsterdam, 1991; 3-22.
5. Janle EM, Kissinger PT. Microdialysis and ultrafiltration. Adv Food Nutr Res 1996; 40: 183-196.
6. Khramov AN, Stenken JA. Enhanced microdialysis extraction efficiency of ibuprofen in vitro by facilitated transport with β-cyclodextrin. Anal Chem 1999; 71: 1257-1264.
7. Khramov AN, Stenken JA. Enhanced microdialysis extraction efficiency of some tricyclic antidepressants and structurally related drugs by cyclodextrin-mediated transport. Analyst 1999; 124: 1027-1033.
8. Kurosaki Y, Nakamura S, Shiojiri Y, Kawasaki H. Lipomicrodialysis: A new microdialysis method for studying the pharmacokinetics of lipophilic substances. Biol Pharm Bull 1998; 21: 194-196.
9. Carneheim C, Ståhle L. Microdialysis of lipophilic compounds: A methodological study. Pharmacol Toxicol 1991; 69: 378-380.
10. Miller WH, Bondinell WE, Cousins RD, et al. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 1999; 9: 1807-1812.
11. Lark MW, Stroup GB, Hwang S-M, et al. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J Pharmacol Exp Ther 1999; 291: 612-617.
12. Ward KW, Salyers KL, Azzarano LM, et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Toxicol Sci 1999; 48: Abstract 973 (Poster reprint available upon request).
13. Ward KW, Azzarano LM, Bondinell WE, et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 1999; 27: 1232-1241.
14. Stenken JA, Topp EM, Southard MZ, Lunte CE. Examination of microdialysis sampling in a well-characterized hydrodynamic system. Anal Chem 1993; 65: 2324-2328.
15. Borg N, Ståhle L. Recovery as a function of the osmolality of the perfusion medium in microdialysis experiments. Anal Chim Acta 1998; 375: 135-141.
16. Szejtli J. Medicinal applications of cyclodextrins. Med Res Rev 1994; 14: 353-386.
17. Lee B-J, Cui J-H, Parrott KA, Ayres JW, Sack RL. Percutaneous absorption and model membrane variations of melatonin in aqueous-based propylene glycol and 2- hydroxypropyl-β-cyclodextrin vehicles. Arch Pharm Res 1998; 21: 503-507.
18. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997, 41: 2714-2718.
19. Gordon IL, Kar R, Opfell RW, Wile AG. Pharmacokinetics of hexamethylmelamine in Intralipid following hepatic regional administration in rabbits. Cancer Res 1987; 47: 5070-5073.